lp

Lp-PLA2-IN-3 is a potent, orally bioactive lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, effectively inhibiting recombinant human [Lp-PLA2] with an IC50 value of 14 nM.

LP-922761 is a potent, selective, and orally active AAK1 inhibitor with inhibitory effects on BMP-2 induced protein kinase (BIKE).

LP-471756 is a specific antagonist of GPR139 and inhibits LP-360924-stimulated cAMP production (IC50 = 640 nM).

LP-360924 is a bioactive chemical.

Lp-PLA2-IN-2 is a selective and potent lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, with an IC50 of 120 nM for recombinant human Lp-PLA2.

LP-6 is a drug-linker conjugate used in the synthesis of antibody-drug conjugates (ADCs). LP-6 consists of an Eg5 inhibitor and a linker [1].

LP-261 is a novel tubulin targeting anticancer agent that binds at the colchicine site on tubulin, inducing G2 M arrest.

Lp-PLA2-IN-10 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2), formerly known as platelet-activating factor acetylhydrolase (PAF-AH). This enzyme catalyzes the hydrolysis of lipoprotein lipids or phospholipids. The compound has research potential in neurodegenerative diseases such as Alzheimer's disease (AD), as well as glaucoma, age-related macular degeneration (AMD), and cardiovascular diseases like atherosclerosis[1].

Lp-PLA2-IN-15 (example 2) is an inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2), showing potential for research in Alzheimer's disease [1].

Lp-PLA2-IN-14 (Compound 19), an inhibitor of rhLp-PLA2, exhibits a potent inhibitory effect with a pIC50 value of 8.4 and is applicable in research on neurodegenerative disorders including Alzheimer Disease (AD), glaucoma, age-related macular degeneration (AMD), and cardiovascular diseases such as atherosclerosis [1].

LP-284 is a potent DNA alkylating agent that kills solid tumors and can be used in hematologic cancer studies with compromised DNA repair, such as mantle cell lymphoma (MCL) [1] [2].

Lp-PLA2-IN-9 (compound 17) is a tetracyclic pyrimidinone compound and a potent inhibitor of Lp-PLA2, targeting rhLp-PLA2 with a pIC50 of 10.1, and has demonstrated research potential in neurodegenerative diseases.

LP 12 hydrochloride is a selective 5-HT7 receptor agonist (Ki=0.13 nM). LP 12 hydrochloride is selective for 5-HT7 over D2, 5-HT1A, and 5-HT2A receptors (Ki values of 224 nM, 60.9 nM, and >1000 nM, respectively).

LP-935509 is a selective, brain-permeable, small molecule competitive inhibitor of articulin-2-associated kinase 1 (AAK1) with an IC50 of 3.3 nM and a Ki of 0.9 nM. LP-935509 is a potent inhibitor of BIKE (IC50 of 14 nM) and a moderate inhibitor of GAK (IC50 of 320±40 nM).

Lp-PLA2-IN-16 (Example 1) is an inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2) with potential applications in Alzheimer's disease research [1].

LP-922761 hydrate is a selective, potent, orally active AAK1 inhibitor with IC50 values of 4.8 nM and 7.6 nM in enzyme and cellular assays, respectively. LP-922761 hydrate inhibits BMP-2 inducible protein kinase (BIKE) (IC50: 24 nM). 922761 hydrate has no significant effect on cellular GAK, opioids, adrenergic α2 or GABAa receptors.

Lp-PLA2-IN-13 (compound 15), a potent Lp-PLA2 inhibitor, shows promise for neurodegenerative disease research [1].

LP-184 (Compound 6), referred to as an acylfulvene analog, demonstrates the ability to inhibit tumor growth with noteworthy anti-cancer efficacy observed across multiple cell lines, including ovarian, colon, prostate, and pancreatic.

ligand of the 5-HT7 receptor

Lp-PLA2-IN-11 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2) with potential applications in diseases associated with Lp-PLA2 activity [e.g., atherosclerosis, Alzheimer's disease].

Lp-PLA2-IN-5 is a potent lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor and an inhibitor of platelet-activating factor acetylhydrolase (PAF-AH), a phospholipase A2 involved in lipoprotein lipid or phospholipid hydrolysis. Lp-PLA2-IN-5 (Compound 35) may have potential applications in studying diseases linked to Lp-PLA2 activity, including Alzheimer's disease and atherosclerosis.

LP-922056 is an inhibitor of Notum Pectinacetylesterase with EC50 values of 21 nM, 55 nM for human and mouse, respectively.

LP-533401 is an inhibitor of Tryptophan hydroxylase 1. It is used for regulates serotonin production in the gut.

Lp-PLA2-IN-17 (Compound 39) acts as an inhibitor of Lp-PLA 2. It is utilized in research to explore disorders associated with the hydrolysis of oxidized lipids into two inflammatory substances mediated by Lp-PLA 2 [1].